Dare Bioscience (DARE) Total Current Liabilities (2013 - 2026)
Dare Bioscience's (DARE) quarterly Total Current Liabilities came in at $23.7 million in Q4 2025, up 9.59% YoY from $21.6 million in Q4 2024, and up 11.64% on a QoQ basis from $21.2 million in Q3 2025.
Dare Bioscience (DARE) Total Current Liabilities (2013 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 13 years of Total Current Liabilities data on file, last reported at $23.7 million in Q4 2025.
- Quarterly Total Current Liabilities rose 9.59% year-over-year to $23.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.7 million (up 9.59% YoY) and the FY2025 annual result came in at $23.7 million, up 9.59% from the prior year.
- Total Current Liabilities advanced to $23.7 million in Q4 2025, from $21.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $31.6 million in Q4 2022 to a low of $6.0 million in Q2 2021.
- A 5-year average of $19.0 million and a median of $19.9 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 175.39% — and 2024, when it sank 50.06%.
- Tracing DARE's Total Current Liabilities over 5 years: stood at $16.1 million in 2021, then surged by 97.0% to $31.6 million in 2022, then tumbled by 35.24% to $20.5 million in 2023, then grew by 5.53% to $21.6 million in 2024, then climbed by 9.59% to $23.7 million in 2025.
- The last three Total Current Liabilities figures came in at $23.7 million (Q4 2025), $21.2 million (Q3 2025), and $19.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Dare Bioscience | 12.35 Mn | -269,456.53 | -132,343.00 | 16.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.92 Mn |
| Dec 31, 2025 | 23.69 Mn |
| Sep 30, 2025 | 21.22 Mn |
| Jun 30, 2025 | 19.22 Mn |
| Mar 31, 2025 | 21.19 Mn |
| Dec 31, 2024 | 21.61 Mn |
| Sep 30, 2024 | 13.16 Mn |
| Jun 30, 2024 | 14.59 Mn |
| Mar 31, 2024 | 17.72 Mn |
| Dec 31, 2023 | 20.48 Mn |
| Sep 30, 2023 | 26.34 Mn |
| Jun 30, 2023 | 24.70 Mn |
| Mar 31, 2023 | 24.34 Mn |
| Dec 31, 2022 | 31.62 Mn |
| Sep 30, 2022 | 22.84 Mn |
| Jun 30, 2022 | 16.54 Mn |
| Mar 31, 2022 | 16.39 Mn |
| Dec 31, 2021 | 16.05 Mn |
| Sep 30, 2021 | 15.91 Mn |
| Jun 30, 2021 | 6.00 Mn |